# V1 Empirics Check — openai/gpt-5.1-codex-mini (Variant A)

**Model:** openai/gpt-5.1-codex-mini
**Variant:** A
**Date:** 2026-04-01T16:41:43.292922

---

**Idea Fidelity**

The paper largely adheres to the manifested idea. It uses the staggered UK rollout of deemed consent (Wales 2015, England 2020, Scotland 2021, Northern Ireland 2023) with NHSBT nation-level data to trace organ donation outcomes, and it frames the key research question—whether opt-out raises deceased donor supply—through a Callaway-Sant’Anna-style staggered DiD implemented as a TWFE specification with nation and year fixed effects. The paper also pursues the novel “organ supply paradox” mechanism by contrasting deemed-consent authorization rates with family override behavior, even though the manifest’s explicit monthly panel is replaced with financial-year data. The paper, however, omits the intended Callaway-Sant’Anna estimator (the manifest mentions CSAN DiD) and instead relies on standard TWFE; this is a meaningful deviation because it sidesteps treatment effect heterogeneity considerations inherent in staggered rollouts. Additionally, the manifest envisioned testing dynamic effects (year 1 vs. year 3) to distinguish law versus cultural shifts, but the paper never presents event-study coefficients or cohort-by-period heterogeneity—only aggregate treatment estimates. These points should be addressed for full fidelity.

---

**Summary**

The paper investigates whether the UK’s staggered switch to deemed consent for organ donation causally increased deceased donor or transplant rates, exploiting the fact that all four nations operate under the same NHSBT infrastructure but adopted opt-out at different times. Using a nation-year panel and a two-way fixed effects specification augmented with randomization inference, it finds no statistically significant effect of deemed consent on deceased donors per million or transplant rates; living donors per million (a placebo) also shows no change. The author then attributes the null to the family override mechanism, documenting that families decline donation in a majority of deemed consent cases, so changing the legal default does little to alter the bedside decision.

---

**Essential Points**

1. **Identification strategy requires richer dynamic and heterogeneity diagnostics.**  
   The paper claims to exploit a staggered adoption of deemed consent, but the TWFE estimator is prone to heterogeneity bias unless treatment effect dynamics are constant. Given the different roll-out years (2016/17 vs. 2020/21 vs. 2021/22 vs. 2023/24) and the pandemic shock, it is essential to show (a) pre-trends for each cohort via event studies, (b) cohort-specific treatment effects, or (c) use of CSAN-style DiD that correctly weights the comparisons. Without this, the null could mask offsetting cohort effects or be driven by differential trends (e.g., Wales’ long pre-treatment trend differs from England’s). The paper should either implement the Callaway-Sant’Anna estimator it advertised or thoroughly justify TWFE’s validity, including showing that ATT estimates are stable across different comparisons.  
   
2. **Timing of treatment and anticipation/covid confounding need clearer handling.**  
   Wales’s legislation went live in December 2015 (partial 2015/16), while England and Scotland implemented mid-2020/2021. The paper codes treatment from the first full financial year but then aggregates into one annual treatment indicator. This compresses much of the variation, especially for Wales with only one clear pre-treatment year in the panel. More importantly, England’s switch coincides with the pandemic, and the treatment indicator may partly capture Covid disruptions (shown by the large negative point estimate for transplants). The paper should clarify how treatment timing is assigned (e.g., does May 2020 count as treated in 2020/21 even though pandemic months dominate?) and demonstrate that results are robust to alternative codings (e.g., calendar-year alignment, lead indicators for anticipation). Taking out England and/or Scotland (or more flexibly controlling for Covid) should be more than a simple drop; show that the treated onset is not confounded with pandemic shocks.

3. **Interpretation of the null needs more nuance and supporting power calculation.**  
   The paper concludes that deemed consent “does not change behavior,” yet the confidence intervals (±5 donors pmp) are wide relative to policy-relevant magnitudes. Considering the pre-treatment mean of 22.7 pmp, a 5 pmp change is economically meaningful (20–25% shift) yet remains within the CI. Without discussing the minimum detectable effect or contextualizing the economic importance of the null, the claim risks overstating the evidence. Presenting a formal power analysis or reporting ATT estimates with confidence intervals (rather than only SEs and RI p-values) would allow readers to assess whether the data can rule out the optimistic effects documented in some cross-country studies. 

If the authors cannot convincingly address these points, particularly the identification concerns, the paper’s causal claims should be substantially tempered or the study might not be publishable in its current empirical form.

---

**Suggestions**

1. **Adopt proper staggered-DiD methods and show dynamics.**  
   Implement the Callaway-Sant’Anna estimator with group-time ATTs, or at least Sun and Abraham (2021) or Baker et al. (2023) to account for treatment heterogeneity. Present cohort-specific ATT estimates (Wales-only, England-only, etc.) and event-study plots to demonstrate parallel trends and visualize dynamics. Even if the data are yearly, using leads/lags helps diagnose violations: for example, plot ATT estimates for \(t=-2,\,-1,\,0,+1, +2\) relative to each nation’s switch. If computational constraints exist, clearly explain and show via supplementary tables that TWFE results align with these more robust estimators.

2. **Refine treatment timing and handle Covid confounding carefully.**  
   Instead of a single treatment indicator, consider modeling the treatment as a function of months or quarters, particularly for England and Scotland where treatment began mid-year. Alternatively, specify “partial treatment” indicators for the fiscal year that straddles the reform, or collapse to calendar-year to compare like with like. Regarding COVID, include explicit controls for pandemic severity (e.g., ICU occupancy or year dummies interacted with broader UK pandemic stages) or instrument the timing to isolate policy from Covid shocks. For robustness, re-estimate restricting the sample to 2015/16–2019/20 and using only Wales as the treated unit; then add England and Scotland sequentially to show consistent signs. Another idea is to weight years by pre-policy trends to mitigate the fact that the pandemic dwarfs the policy effect.

3. **Quantify the statistical power and contextualize magnitudes.**  
   Use pre-treatment variation to calculate the minimum detectable effect (MDE) with 80% power given the panel’s degrees of freedom, or provide confidence intervals around ATTs. Present the implied effect size relative to total donors (e.g., “a 1.63 pmp decline equals ~95 donors UK-wide per year”). Such framing clarifies whether the null is “meaningfully zero” or simply imprecise. Present additional placebo outcomes beyond living donors (e.g., donors for which consent defaults are irrelevant) to further rule out spurious noise.

4. **Expand mechanism section with microdata evidence.**  
   The paper’s discussion of family overrides is compelling but relies on national-level aggregates. If possible, include more granular evidence, such as the share of referrals that proceed to donation by consent type or time trends in family override rates pre- vs. post-legislation. If NHSBT PDA reports include patient-level success rates, compute the share of donations blocked due to family refusal in deemed consent vs. opt-in cases. Even descriptive tables showing the weight of family override in the consent pipeline would strengthen the mechanistic claim.

5. **Clarify why living donors make a good placebo and mention potential caveats.**  
   The living donor placebo is intuitive, but explain why placebos like “eligible donors referred” or “family support conversations” were not used. Also, clarify that living donation may react to broader transplant system shocks (e.g., hospital capacity), so matching on hospital-level trends or explicitly stating why living donation should remain unaffected would preempt criticisms.

6. **Address the asymmetry between expressed registration and deemed consent.**  
   The paper asserts that expressed opt-in leads to high authorization. To make this actionable, consider exploiting variation in registration campaigns across nations or years. For example, if one nation had an ODR drive (e.g., linked to driving license renewals) and the others did not, that quasi-experiment could show how increasing expressed registrations affects actual donors. If no such variation exists, at least discuss whether registration data vary with policy rollouts or time; this contextualizes the suggested policy shift.

7. **Report robustness to different sample definitions and functional forms.**  
   Supplement Table 4 with a specification that uses calendar-year data, another that weights by population, and a model that uses a logistic transformation of consent rates (if the author later investigates consent outcomes). These variations would reassure readers that the null is not a byproduct of the specific panel or scale (levels vs. logs).

8. **Discuss the role of Northern Ireland as (initially) never-treated control.**  
   Since Northern Ireland only became opt-out in 2023, in the early periods it serves as a control. However, given its small population and potential differences in timing, explicitly discuss its suitability as a control (e.g., confirm that pre-trends between Northern Ireland and the treated nations are parallel). Including a figure of nation-specific outcomes over time would make this clearer.

9. **Enhance the narrative on policy implications.**  
   The conclusion rightly shifts attention to expressed registration and the bedside conversation, but the policy takeaway could be sharper. For instance, specify what “improving the bedside conversation” entails (e.g., communications training, third-party mediators, grief support), and suggest how the null result informs future legislative efforts in other countries. This gives practitioners concrete guidance.

10. **Ensure the appendix tables are correctly labeled.**  
   The appendix table currently mixes classification language (“Large negative”) with the main text. Consider aligning terminology with the main narrative and clarifying how SDEs are computed (e.g., what is SD(Y)?). If this table is retained, tie it back to the main identification points: does the standardized effect corroborate the null? If not essential, drop it to keep the focus on the main DiD results.

By implementing these suggestions, the paper would more convincingly demonstrate that the UK’s opt-out rollout provides a credible within-system test of detected default effects, and it would better inform debates about whether policy should focus on legal frameworks or the clinical and social pathways that actually govern organ donation.
